MeSH term
Frequency | Condition_Probility | *Adjuvants, Immunologic | 2 | 6.0 |
Administration, Intranasal | 4 | 4.0 |
Administration, Oral | 2 | 0.0 |
Animals | 9 | 0.0 |
Escherichia coli/*immunology | 3 | 8.0 |
*Escherichia coli Proteins | 7 | 3.0 |
Female | 7 | 0.0 |
Humans | 15 | 0.0 |
Mice | 5 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 8 | 0.0 |
Comparative Study | 2 | 0.0 |
In Vitro | 2 | 0.0 |
Molecular Structure | 2 | 0.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Adult | 2 | 0.0 |
English Abstract | 2 | 0.0 |
Influenza/prevention & control | 2 | 25.0 |
Male | 5 | 0.0 |
Middle Aged | 2 | 0.0 |
Guinea Pigs | 2 | 0.0 |
Plasmids | 3 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Escherichia coli | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
DNA, Recombinant | 2 | 1.0 |
Rats | 2 | 0.0 |
Immunoglobulin G/metabolism | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 2 | 0.0 |